Nucleotide sequence analysis of the gyrA genes of 10 spontaneous quinolone-resistant gyrA mutants of Escherichia coli KL16, including four mutants examined previously, disclosed that quinolone resistance was caused by a point mutation within the region between amino acids 67 and 106, especially in the vicinity of amino acid 83, of the GyrA protein.Quinolones are considered to exert antibacterial activity by inhibiting DNA gyrase (EC 5.99.1.3), which catalyzes topological changes of DNA (4, 11). DNA gyrase of Escherichia coli consists of subunits A and B, which are the products of the gyrA and gyrB genes, respectively. Mutations in either gene can cause quinolone resistance (4,(15)(16)(17) were determined by dideoxy-chain termination (9) with phage M13mpl8 and M13mpl9 vectors. Table 1 shows the sites and types of mutations and the levels of resistance to quinolones of 10 quinolone-resistant gyrA mutants of E. coli KL16. Four mutants (N-51, P-18, P-10, and N-89) were analyzed previously (17). All 10 point mutations were considered to be solely responsible for quinolone resistance, because replacement of the 0.6-kilobase Sacl-SmaI fragment containing the mutations by the corresponding fragment from wild-type gyrA gene resulted in complete loss of quinolone resistance (data not shown). Sequencing of the 0.6-kilobase SacI-SmaI fragments of the mutant gyrA genes revealed that these mutations were located within a relatively small region (amino acids 67 through 106) of the A subunit, which we call a quinolone resistance-determining region. There were no other mutations in all of the sequenced fragments. Eight of the 10 mutations were in a limited area (amino acids 81 through 87) of the region; surprisingly, five mutations were situated at the same site of amino acid 83. The levels of resistance to quinolones seemed to be related to the mutation sites, because quinolone MICs were high in the decreasing order of MICs for mutants with mutations at amino acids 83, 87, 81, 84, 67, and 106. This result suggests the importance of an area around amino acid 83 of the gyrase A subunit for determining quinolone resistance.Amino acid changes detected at amino acid 83 were Ser to
The norA gene cloned from chromosomal DNA of quinolone-resistant Staphylococcus aureus TK2566 conferred relatively high resistance to hydrophilic quinolones such as norfloxacin, enoxacin, ofloxacin, and ciprofloxacin, but only low or no resistance at all to hydrophobic ones such as nalidixic acid, oxolinic acid, and sparfloxacin in S. aureus and Escherichia coli. The The increase in methicillin-resistant Staphylococcus aureus is a serious problem because only a few effective agents are clinically available. Some quinolones have been used for the treatment of methicillin-resistant S. aureus infections, but the emergence of quinolone resistance has been reported elsewhere (32). Unlike the mechanism underlying the quinolone resistance of gram-negative bacteria such as Escherichia coli (2,7,9,11,12,15,27,31,(36)(37)(38)(39) and Pseudomonas aeruginosa (4,13,16,29,30,36,40)
Angiotensin type 2 receptor gene null mutant mice display congenital anomalies of the kidney and urinary tract (CAKUT). Various features of mouse CAKUT impressively mimic human CAKUT. Studies of the human type 2 receptor (AGTR2) gene in two independent cohorts found that a significant association exists between CAKUT and a nucleotide transition within the lariat branchpoint motif of intron 1, which perturbs AGTR2 mRNA splicing efficiency. AGTR2, therefore, has a significant ontogenic role for the kidney and urinary tract system. Studies revealed that the establishment of CAKUT is preceded by delayed apoptosis of undifferentiated mesenchymal cells surrounding the urinary tract during key ontogenic events, from the ureteral budding to the expansive growth of the kidney and ureter.
DNA methylation is globally reprogrammed during mammalian preimplantation development, which is critical for normal development. Recent reduced representation bisulfite sequencing (RRBS) studies suggest that the methylome dynamics are essentially conserved between human and mouse early embryos. RRBS is known to cover 5–10% of all genomic CpGs, favoring those contained within CpG-rich regions. To obtain an unbiased and more complete representation of the methylome during early human development, we performed whole genome bisulfite sequencing of human gametes and blastocysts that covered>70% of all genomic CpGs. We found that the maternal genome was demethylated to a much lesser extent in human blastocysts than in mouse blastocysts, which could contribute to an increased number of imprinted differentially methylated regions in the human genome. Global demethylation of the paternal genome was confirmed, but SINE-VNTR-Alu elements and some other tandem repeat-containing regions were found to be specifically protected from this global demethylation. Furthermore, centromeric satellite repeats were hypermethylated in human oocytes but not in mouse oocytes, which might be explained by differential expression of de novo DNA methyltransferases. These data highlight both conserved and species-specific regulation of DNA methylation during early mammalian development. Our work provides further information critical for understanding the epigenetic processes underlying differentiation and pluripotency during early human development.
Thirteen spontaneous quinolone-resistant gyrB mutants of Escherichia coli KL16, including two that were examined previously, were divided into two types according to their quinolone resistance patterns. Type 1 mutants were resistant to all the quinolones tested, while type 2 mutants were resistant to acidic quinolones and were hypersusceptible to amphoteric quinolones. Nucleotide sequence analysis disclosed that all nine type 1 mutants had a point mutation from aspartic acid to asparagine at amino acid 426 and that all four type 2 mutants had a point mutation from lysine to glutamic acid at amino acid 447. Quinolones are a group of antibacterial agents whose target is DNA gyrase (EC 5.99.1.3), an enzyme that catalyzes topological changes of DNA (4). The DNA gyrase of Escherichia coli consists of two A and two B subunits, which are the products of the gyrA (48 min) and gyrB (83 min) genes, respectively (3,7,11,21,29). Mutations in the gyrA gene are as frequent as those in the gyrB gene in spontaneous quinolone-resistant mutants of E. coli KL16, although the majority of quinolone-resistant clinical E. coli isolates have gyrA mutations (23). In the gyrA gene, quinolone resistance is caused by a point mutation within the relatively narrow region of amino acids 67 to 106, which is called the quinolone resistance-determining region (34, 35). In the gyrB gene, two quinolone resistance-determining sites (amino acids 426 and 447) have been found (32,33). To obtain more information on the region responsible for quinolone resistance in the gyrB gene, 11 additional quinolone-resistant gyrB mutants of E. coli KL16 were analyzed.MATERIALS AND METHODS Strains. Quinolone-resistant mutants of E. coli KL16 were isolated by plating the organism on LB agar (18) containing nalidixic acid or enoxacin at four times the MIC, and gyrB mutants were identified by transformation with the wild-type gyrB gene as described previously (23).Reagents, plasmids, and phages. Nalidixic acid (14) Cloning and sequencing of the E. coli gyrB genes. HindIII DNA fragments of about 13 kb in size containing the gyrB gene were cloned from quinolone-resistant gyrB mutants of E. coli KL16 as described previously (33). Nucleotide sequences were determined by the dideoxy-chain termination method (17) by using phage M13mpl8 and M13mpl9 vectors. RESULTS AND DISCUSSIONThe levels of resistance or hypersusceptibility (the increase or decrease in MIC compared with that for E. coli KL16) to various quinolones of 13 quinolone-resistant gyrB mutants of E. coli KL16 are given in Table 1. The MICs of some quinolones for N-24 and N-31 were not identical to those reported previously (23, 32) but were within experimental fluctuations. All the mutants could be divided into two types with respect to their quinolone resistance. Type 1 mutants were resistant to all the quinolones tested, while type 2 mutants were resistant to acidic quinolones, such as nalidixic acid, oxolinic acid, cinoxacin, piromidic acid, and flumequine but were hypersusceptible to amphoteric quinolones, ...
Elevated levels of endogenous angiotensin can cause hypertensive nephrosclerosis as a result of the potent vasopressor action of the peptide. We have produced by gene targeting mice homozygous for a null mutation in the angiotensinogen gene (Atg-'-). Postnatally, Atg-'-animals show a modest delay in glomerular maturation. Although Atg-'-animals are hypotensive by 7 wk of age, they develop, by 3 wk of age, pronounced lesions in the renal cortex, similar to those of hypertensive nephrosclerosis. In addition, the papillae of homozygous mutant kidneys are reduced in size. These lesions are accompanied by local up-regulation of PDGF-B and TGF-fi1 mRNA in the cortex and down-regulation of PDGF-A mRNA in the papilla. The study demonstrates an important requirement for angiotensin in achieving and maintaining the normal morphology of the kidney. The mechanism through which angiotensin maintains the volume homeostasis in mammals includes promotion of the maturational growth of the papilla. (J. Clin. Invest. 1995.
Therapy with human recombinant erythropoietin (EPO) has been accepted as effective for renal anemia in dialysis patients. However, studies in rats have shown that correcting anemia with EPO may affect the progression of renal dysfunction. In humans, however, the effect of EPO on residual renal function is a matter of controversy. We, therefore, investigated whether the long-term administration of EPO to predialysis patients influences residual renal function. Anemic patients at the predialysis stage with a serum creatinine (Cr) concentration ranging from 2 to 4 (average 2.9) mg/dl and a hematocrit (Ht) of less than 30% were randomly assigned to two groups which consisted of anemic patients not treated with EPO (group I, untreated anemic controls, n = 31) and anemic patients treated with EPO (group II, treated anemics, n = 42). Patients with nonsevere or moderate anemia (Ht > 30%) with a Cr ranging from 2 to 4 (average 2.6) mg/dl were also recruited as nonanemic controls (group III, untreated nonanemic controls, n = 35). Blood pressure was controlled to the same degree among the three groups by combined treatment with calcium antagonists and angiotensin-converting enzyme inhibitors. All patients were kept strictly on a low-protein (0.6 g/kg/day) and a low-salt (7 g/day) diet. The degree of control of dietary protein and blood pressure and the frequency of angiotensin-converting enzyme inhibitor administration were comparable among the three groups. The primary end point for each patient was a doubling of the baseline Cr which yielded cumulative renal survival rates which were plotted against time. Ht rose significantly from 27.0 ± 2.3 to 32.1 ± 3.2% in group II (n = 42, p < 0.001) with a rate of increase of 0.4 ± 0.06%/week. However, it declined from 27.9 ± 1.8 to 25.3 ± 1.9% in group I (n = 31, p < 0.001) and from 35.9 ± 3.5 to 32.2 ± 3.9% in group III (n = 35, p < 0.001). Cr doubled in 26 patients (84%) in group I as compared with 22 (52%) in group II and 21 (60%) in group III. The cumulative renal survival rates in groups II and III were significantly better than that in group I: p = 0.0003 (group I vs. group II) and p = 0.0024 (group I vs. group III). However, there was no difference in the renal survival rate between groups II and III (p = 0.3111). The better survival rate obtained in group II was attributable to the better survival rate for the nondiabetic patients in this group. The present study suggests that anemia, per se, is a factor in the progression of end-stage renal failure and that reversal of anemia by EPO can retard the progression of renal failure, especially in nondiabetic patiens, provided that blood pressure control, rate of increase in Ht, and dietary protein restriction are appropriate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.